Abstract
The identification and development of novel nontoxic phytochemicals that target androgen and androgen receptor (AR) signaling remains a priority for prostate cancer (PCA) control. In the present study, we assessed the antiandrogenic efficacy of isosilybin B employing human PCA LNCaP (mutated AR), 22Rv1 (mutated AR) and LAPC4 (wild-type AR) cells. Isosilybin B (10–90 μM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells. Isosilybin B treatment also inhibited synthetic androgen R1881-induced nuclear localization of AR, PSA expression and cell growth, and caused G1 arrest. In mechanistic studies identifying AR degradation, isosilybin B caused increased phosphorylation of Akt (Ser-473 and Thr-308) and Mdm2 (Ser-166), which was linked with AR degradation as pretreatment with PI3K inhibitor (LY294002)-restored AR level. Further, overexpression of kinase-dead Akt largely reversed isosilybin B mediated-AR degradation suggesting a critical role of Akt in AR degradation. Antibody pull-down results also indicated that isosilybin B treatment enhances the formation of complex between Akt, Mdm2 and AR, which promotes phosphorylation-dependent AR ubiquitination and its degradation by proteasome. Together, present findings identify a novel mechanism for isosilybin B-mediated anticancer effects in human PCA cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH . (2003). Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 112: 1724–1731.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33–39.
Chen L, Gilkes DM, Pan Y, Lane WS, Chen J . (2005). ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 24: 3411–3422.
Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP . (2006). Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103: 15969–15974.
Cinar B, De Benedetti A, Freeman MR . (2005). Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin. Cancer Res 65: 2547–2553.
Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC et al. (2005). Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 65: 4448–4457.
Deep G, Oberlies NH, Kroll DJ, Agarwal R . (2007). Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis 28: 1533–1542.
Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R . (2006). Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25: 1053–1069.
Dhanalakshmi S, Agarwal C, Singh RP, Agarwal R . (2005). Silibinin up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells. J Biol Chem 280: 20375–20383.
Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST et al. (2006). Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 20: 503–515.
Grossmann ME, Huang H, Tindall DJ . (2001). Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687–1697.
Haag P, Bektic J, Bartsch G, Klocker H, Eder IE . (2005). Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96: 251–258.
Hershko A, Ciechanover A . (1998). The ubiquitin system. Annu Rev Biochem 67: 425–479.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ . (2007). Cancer statistics, 2007. CA Cancer J Clin 57: 43–66.
Kim NC, Graf TN, Sparacino CM, Wani MC, Wall ME . (2003). Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem 1: 1684–1689.
Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR et al. (1997). Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3: 402–408.
Lee DK, Chang C . (2003a). Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 88: 4043–4054.
Lee HJ, Chang C . (2003b). Recent advances in androgen receptor action. Cell Mol Life Sci 60: 1613–1622.
Liao Z, Wang S, Boileau TW, Erdman Jr JW, Clinton SK . (2005). Increased phospho-AKT is associated with loss of the androgen receptor during the progression of N-methyl-N-nitrosourea-induced prostate carcinogenesis in rats. Prostate 64: 186–199.
Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C . (2002). Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21: 4037–4048.
Lin HK, Yeh S, Kang HY, Chang C . (2001). Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98: 7200–7205.
Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D . (2002). Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62: 5485–5488.
Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C . (2005). Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog 44: 1–10.
Muller MM, Schreiber E, Schaffner W, Matthias P . (1989). Rapid test for in vivo stability and DNA binding of mutated octamer binding proteins with ‘mini-extracts’ prepared from transfected cells. Nucleic Acids Res 17: 6420.
Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S et al. (1996). CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 56: 3042–3046.
Nelson WG, De Marzo AM, Isaacs WB . (2003). Prostate cancer. N Engl J Med 349: 366–381.
Paajarvi G, Roudier E, Crisby M, Hogberg J, Stenius U . (2005). HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J 19: 476–478.
Pan Y, Chen J . (2003). MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 23: 5113–5121.
Pliskova M, Vondracek J, Kren V, Gazak R, Sedmera P, Walterova D et al. (2005). Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 215: 80–89.
Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH et al. (2006). Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98: 1408–1423.
Seidlova-Wuttke D, Becker T, Christoffel V, Jarry H, Wuttke W . (2003). Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J Steroid Biochem Mol Biol 86: 179–188.
Sharifi N, Farrar WL . (2006). Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am J Ther 13: 166–170.
Singh RP, Agarwal R . (2002). Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 4: 655–663.
Singh RP, Agarwal R . (2006). Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45: 436–442.
Tong Q, Zhao J, Chen Z, Zeng F, Lu G . (2003). Effects of blocking androgen receptor expression with specific hammerhead ribozyme on in vitro growth of prostate cancer cell line. Chin Med J (Engl) 116: 1515–1518.
Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C . (2004). Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 279: 32444–32452.
Wellington K, Jarvis B . (2001). Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15: 465–489.
Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH et al. (2000). HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841–6845.
Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E et al. (2005). Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 280: 33558–33565.
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC . (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973–982.
Zi X, Agarwal R . (1999). Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 96: 7490–7495.
Zi X, Feyes DK, Agarwal R . (1998). Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 4: 1055–1064.
Acknowledgements
We thank Tyler N Graf, MS for preparative isolation of the pure flavonolignans used in these studies. This work was supported by NCI RO1 CA104286 (to DJK and RA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deep, G., Oberlies, N., Kroll, D. et al. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 27, 3986–3998 (2008). https://doi.org/10.1038/onc.2008.45
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.45
Keywords
This article is cited by
-
The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1
Cell Death & Disease (2018)
-
Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy
Oncogene (2009)
-
Selective apoptosis induction by the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide is achieved by modulating mitochondrial bioenergetics in premalignant and malignant human prostate epithelial cells
Apoptosis (2009)